Patent expiry changes the economics of a successful medicine. A product that once generated strong cash flow with few direct substitutes can face competition for the same prescriptions, often at lower prices. For investors, the useful question is how much revenue and profit will remain after competitors enter, and how quickly the change will occur. Small molecule drugs face generic competition; many biologic medicines, biosimilar competition. Their approval requirements and routes to market differ, so their revenue forecasts should differ too. Neither deserves a mechanical assumption that sales disappear on a patent anniversary, or that a familiar brand will retain its customers indefinitely.
Patent Expiry Is Not the Same as Commercial Competition
A patent expiration date is one part of a launch timeline. In the United States, patents and regulatory exclusivity are separate protections, governed by different statutes, and their periods need not coincide. A patent protects the invention covered by its claims; regulatory exclusivity can delay or prevent approval of competing applications under the applicable rules. The end of one protection does not establish that every barrier to entry has ended. The FDA’s explanation of patents and exclusivity sets out that distinction. An investor should therefore resist treating the earliest date in a patent table as a confirmed date for unrestricted competition.
Build a timeline around the product, presentation and territory being valued. Record the relevant protection dates, disclosed litigation or settlement terms, competitor approval status and evidence of launch preparation. Then identify the point at which an entrant could supply meaningful volumes. Those are separate questions. An approved competitor without a clear route to launch should carry a different forecast assumption from one already shipping product. The broader mechanics of protection belong in the guide to biotech patents and regulatory exclusivity; the task here is translating the remaining protection into a defensible revenue timeline.
Generic Competition and Biosimilars Follow Different Paths
Generics compete against an established active ingredient
A generic medicine contains the same active substance as its reference medicine, although inactive ingredients, packaging and appearance can differ. Its development relies on established evidence about that active substance, with quality and appropriate equivalence evidence supporting the application. The EMA’s generic and hybrid medicines framework describes these requirements. Commercially, the investor must work out how readily demand can move between approved products. Where competing versions can serve the same prescriptions and buyers have an incentive to choose lower prices, the originator faces pressure on both market share and the price it can retain.
Biosimilarity and interchangeability answer different questions
A biosimilar is highly similar to its reference biologic, with no clinically meaningful differences in safety and effectiveness. Biological products are more complex than conventional drugs, and minor manufacturing variation does not establish inferior treatment performance. In the United States, an interchangeable biosimilar may be substituted at the pharmacy without consulting the prescriber, subject to state law. That designation concerns substitution; it does not mean the product is safer or more effective than another approved biosimilar. These distinctions are covered in the FDA’s biosimilar and interchangeability guidance for patients. For valuation, separate the scientific approval question from the commercial question of who selects, purchases and dispenses the medicine.
Do not export the US terminology into every market. In the European Union, approved biosimilars are considered interchangeable from a scientific perspective, within their approved conditions of use, but individual member states manage switching and substitution arrangements. The joint EMA–HMA statement on biosimilar interchangeability makes that division clear. A global forecast therefore needs territorial assumptions. A substitution pathway that matters in one country may not determine purchasing in another, and a single worldwide erosion percentage can hide the markets that contribute most of the product’s profit.
| Forecast input | Generic competition | Biosimilar competition |
|---|---|---|
| Route to demand | Assess dispensing, purchasing contracts and substitution opportunities. | Assess prescribing, pharmacy coverage, hospital purchasing and switching arrangements. |
| Competitive supply | Count credible suppliers for the relevant strength and dosage form. | Check manufacturing readiness and commercial supply commitments. |
| Price pressure | Test how additional suppliers affect retained net price. | Test discounts, contracting responses and access to covered patients. |
| Originator retention | Require evidence for any durable branded sales assumption. | Require evidence for retained access, volume and net price. |
What Determines the Speed of Revenue Erosion?
The number of announced competitors is a weak starting point unless each entrant can reach customers. Build the competitive set from products that could actually compete during the forecast period. Check the relevant dosage form, approved uses, launch rights, supply capacity and commercial partner. One well supplied entrant with purchasing access can deserve more weight than several distant development programs. Conversely, a crowded pipeline does not establish simultaneous launches. This is an application of assessing drug competition and treatment differentiation, with particular attention to how many suppliers can serve the same demand rather than how many names appear in an investor presentation.
Product complexity also belongs in the forecast, but it needs evidence. A difficult formulation or production process may raise the work required to enter a market. It does not justify an indefinite assumption of protection. Ask what the competitor has already demonstrated, which production steps remain unresolved, and whether commercial inventory is available. For the originator, examine its own cost base as volumes decline: unused capacity can weaken the economics of retaining a smaller franchise. The relevant questions sit within biotech manufacturing, capacity and production costs. Manufacturing is a forecast input, not a substitute for checking the legal and regulatory position.
Price retention and volume retention are separate assumptions
A brand can defend prescriptions by accepting a lower realised price. It can also lose prescriptions while retaining relatively attractive pricing among the customers who remain. These outcomes have different profit implications, even when reported revenue ends up similar. Track net revenue per comparable treatment unit rather than relying on published list prices. Rebates, discounts and other deductions create a gap between a headline price and the amount retained by the manufacturer. The mechanics of drug pricing, reimbursement and market access matter because a price concession may preserve access without preserving the original economics. Retained market share, by itself, is not evidence that a franchise has resisted erosion.
Separate existing patients from new treatment starts where the available data allow it. A scenario in which established users remain on the originator but new patients receive competitors can produce a gradual decline. A scenario involving broad purchasing or coverage changes can move demand more abruptly. Treat these as hypotheses to test against disclosed contracts, prescription trends and management commentary, rather than universal rules about patient behaviour. Also distinguish manufacturer shipments from end demand. A quarter affected by inventory movement should not automatically reset a multiyear forecast. The most useful operating update explains what changed in demand, what changed in price, and whether either movement is expected to persist.
Revlimid and Humira Show Why Timing and Portfolio Context Matter
Revlimid: entry can occur in stages
Bristol Myers Squibb’s Revlimid provides a concrete example of a staged competitive transition. Certain US generic lenalidomide licenses initially carried volume restrictions; those restrictions ended on January 31, 2026. Revlimid’s US revenue had already fallen 49% in 2025, reflecting lower demand driven by generic erosion and lower average net selling prices. The pricing movement also included effects from Medicare Part D redesign and government channel mix, so attributing the entire decline to generic competition would be inaccurate. These details appear in Bristol Myers Squibb’s 2025 Form 10-K. The analytical lesson is to model the disclosed phases of competition, including changes in permitted volumes, rather than choosing one patent date and applying a uniform annual decline.
Humira: a declining product and a growing company can coexist
AbbVie’s 2025 results illustrate a different distinction. Global Humira revenue fell 49.5% to $4.540 billion, while US Humira revenue fell 57.1%. At company level, net revenue increased 8.6% to $61.160 billion. Skyrizi generated $17.562 billion and Rinvoq, $8.304 billion. The figures are reported in AbbVie’s full-year 2025 financial results. This is a useful warning against equating product erosion with an identical decline across the business. It also challenges the assumption that a biologic must retain revenue gently. Assess the exposed franchise on its own economics, then examine whether the rest of the portfolio can replace the lost contribution after its own costs.
Build the Forecast From Volume, Net Price and Timing
Start with a clean baseline for each major territory. Identify the last period before meaningful competitive entry, then check whether it contains inventory movements, unusual rebates or temporary demand. Use comparable treatment units where possible, rather than mixing pack sizes or strengths. A practical first model holds the underlying treatment pool constant and varies the originator’s retained volume and net price. Later, add market growth, changing treatment duration or competition from different therapies where evidence supports them. Keep these assumptions visible. Otherwise, an apparently cautious erosion rate can conceal an optimistic market growth forecast doing most of the work.
Illustrative retained revenue = pre-entry revenue × retained treatment volume × retained net price. Both retention percentages are measured against the pre-entry baseline. They are multiplied, not added. For a hypothetical product with $1 billion in annual revenue, retaining 60% of treatment volume and 80% of net price produces $480 million in annualised revenue. The following scenarios are arithmetic examples, not historical benchmarks or predictions for a particular drug.
| Scenario | Volume retained | Net price retained | Annualised revenue |
|---|---|---|---|
| Contained pressure | 80% | 90% | $720 million |
| Moderate pressure | 60% | 80% | $480 million |
| Heavy pressure | 35% | 65% | $227.5 million |
| Severe pressure | 15% | 50% | $75 million |
Calendar timing can disguise the eventual effect. Suppose the moderate scenario begins exactly halfway through a year and takes effect immediately. With no seasonality or inventory movement, half a year at the original $1 billion annual rate plus half at $480 million produces $740 million of revenue. The next full year would be $480 million if those conditions persisted. A relatively modest first-year decline would therefore provide little reassurance about the subsequent year. Test entry dates alongside retained price and volume in valuation sensitivity analysis, particularly when a launch could move across a reporting year or coincide with a major purchasing decision.
Translate the revenue curve into cash flow
Revenue erosion and profit erosion need separate calculations. Lower volume may reduce variable production costs, but other expenses do not disappear on the same schedule. Manufacturing commitments, commercial contracts and restructuring costs can affect the cash retained during a transition. Set out which costs fall with units, which can be removed later, and which remain shared across the business. Then model the residual franchise with those costs attached. A revenue tail is not automatically a valuable cash flow tail. Equally, a shrinking product can still contribute cash if the remaining cost base supports it. The answer depends on the numbers, not the direction of sales alone.
For valuation, use an explicit post-entry period instead of allowing protected economics to drift into a terminal value. Any continuing sales assumption needs a reason, and any stable margin assumption needs one too. A declining franchise should not acquire perpetual growth simply because the spreadsheet ends. Incorporate the resulting cash flows into risk-adjusted pipeline valuation, separating the established product from replacement assets that still face development risk. This also prevents double counting: the cash generated by the mature medicine cannot simultaneously fund a new program and remain available for distribution without recognising that spending.
Evaluate the Originator and the Challenger Separately
For the originator, estimate how much dependable cash generation is exposed and when replacement products must contribute. Compare profits rather than matching lost revenue dollar for dollar. A new launch may require spending before it produces a meaningful return, and an unapproved asset should not receive the same certainty as an established product. For a smaller biotech, the erosion of its commercial medicine can also change the financing timetable. Recalculate cash burn and cash runway using the competitive sales curve, not a continuation of the most recent quarter. Check whether the company remains funded through its next development milestone under a harsher erosion case.
For a generic or biosimilar challenger, the reference product’s historical sales are a starting point for research, not a revenue opportunity to copy into a model. Estimate the market after competitive pricing, then the share the entrant could obtain, and finally the economics it retains after partner payments and commercial costs. Approval alone does not answer those questions. Evidence of supply, purchasing access and execution deserves separate attention, as covered in drug launches and adoption. A challenger can gain substantial volume yet earn a disappointing return if its price assumptions were too generous or its cost to serve the market was underestimated.
Licensing structures add another layer. An originator may retain economics through a disclosed supply or licensing arrangement; a biotech partner may receive royalties rather than record the full product sale. Model the actual payment base and contractual terms. Do not assume royalties continue for the same duration as residual prescriptions, or that every dollar of end-market revenue carries the headline royalty rate. The relevant contract may contain deductions, territorial differences or changes in payments over time. These questions belong alongside valuing biotech licensing deals, especially when the investor owns the rights holder rather than the company selling the medicine.
Assess Defences Without Assuming They Will Work
A company facing expiry may present a new formulation, delivery device, dosing schedule or successor therapy as protection for the franchise. Evaluate each proposition on its own. Ask whether it offers a practical benefit, which patients could receive it, what evidence supports adoption, and what price the company could retain. Moving sales into a successor product is not a sufficient forecast assumption by itself. The model needs to show how that movement happens and what it costs. Avoid transferring the old product’s entire sales base into a new brand while also leaving a generous residual tail in the original product; that counts the same demand twice.
Apply the same discipline to cost reductions and dealmaking. A planned reduction in spending should have a timetable and a credible relationship to the affected business. An acquisition intended to replace lost earnings has a purchase price, financing requirements and its own execution risks. Keep a bridge from the exposed franchise’s profit contribution to the company’s expected cash generation after these actions. That bridge makes unsupported optimism easier to spot. It also keeps the analysis focused on what shareholders own: a business with contractual obligations and competing uses of cash, rather than a collection of product revenue targets.
What to Check in Each Reporting Period
Maintain a dated evidence file rather than rebuilding the argument from each earnings headline. Save the documents supporting launch rights, commercial entry and financial performance, then record which forecast assumption each document changes. Distinguish a company’s expectation from an event that has happened. Competitor approval, shipment commencement and a disclosed purchasing agreement should not be treated as interchangeable milestones. The guide to researching biotech through filings and other primary records provides the broader research process. For a medicine approaching or experiencing competitive entry, the working file should answer a short set of operational questions:
- Which competitors are approved, launched and supplying the relevant market?
- Have disclosed launch restrictions, settlement terms or supply arrangements changed?
- How much of the reported sales movement reflects volume, net price, currency or inventory?
- What evidence supports the originator’s remaining market access and sales tail?
- Which costs have actually fallen, and which savings remain forecasts?
- What observable development would invalidate the current erosion scenario?
Attach a revision trigger to the assumptions that matter most. A competitor launch can change the entry date; a contract change, the accessible volume; a pricing disclosure, the net revenue forecast. Update those inputs before changing the valuation multiple. Where the company does not disclose enough detail, retain a wider scenario range rather than manufacturing precision. The useful output is a forecast whose moving parts can be checked against subsequent evidence, including a clear record of why an expected decline did—or did not—arrive on schedule.